NovaBios埃博拉病毒试纸条

美国NovaBios埃博拉病毒试纸条

广州健仑生物科技有限公司

本司长期供应埃博拉病毒检测试剂盒，其主要品牌包括美国NovaBios、广州创仑等CDC使用的产品，试剂盒的实验方法包括胶体金方法、ELISA方法、PCR方法等。

欢迎咨询

欢迎咨询2042552662

埃博拉病毒IgM、IgG、ELISA检测试剂、埃博拉快速检测试剂盒、

埃博拉病毒核酸检测试剂盒（荧光探针PCR）

西非工作、旅游埃博拉检测试剂盒

美国CDC使用的埃博拉诊断试剂——美国的NovaBios

美国NovaBios埃博拉病毒试纸条

【埃博拉简介】

埃博拉（Ebola virus）又译作伊波拉病毒。是一种十分罕见的病毒，1976年在苏丹南部和刚果（金）（旧称扎伊尔）的埃博拉河地区发现它的存在后，引起医学界的广泛关注和重视，“埃博拉”由此而得名。是一个用来称呼一群属于纤维病毒科埃博拉病毒属下数种病毒的通用术语。是一种能引起人类和灵长类动物产生埃博拉出血热的烈性传染病病毒，有很高的死亡率，在50%至90%之间，致死原因主要为中风、心肌梗塞、低血容量休克或多发性器官衰竭。

埃博拉出血热（EBHF）是由一种丝状病毒感染导致的急性出血性、动物源性传染病。1976年，埃博拉出血热在非洲的苏丹和扎伊尔暴发，病死率高达50% ～ 90% 。因该病始发于扎伊尔北部的埃博拉河流，并在该区域严重流行，故命名为埃博拉病毒，其形态学、致病性等与马尔堡病毒相似，但免疫原性有所区别。

【产品介绍】

该产品是世界卫生组织（WHO）*个批准用于埃博拉病毒检测的诊断试剂卡。不需要借助其他实验仪器设备，只需要采取几滴血清、血浆、血液样品，既可以检测，并在15分钟内就可以得知结果是否感染埃博拉病毒。该产品具有灵敏度高、操作方便、实验时间短等特点。

美国NovaBios埃博拉病毒试纸条

上述试验结果证实有效性后，研究人员将接种范围扩大至6岁以上的儿童，共有1677人立即接种了疫苗，其中包括194名儿童。结果显示，他们也得到了有效防护，没有患上埃博拉出血热。
　　在接种疫苗的5837人中，约一半的人出现了头痛、疲劳和肌肉酸痛等轻微的不良反应，个别人不良反应较重，但他们的身体都在数天内恢复了，并没有产生长期影响。在一直没有接种疫苗的人中，共有7人患上了埃博拉出血热。
生产疫苗的美国默沙东公司已经获得美国和欧盟方面的一些资格认证，这有利于相关监管机构加快审核这种新疫苗，使其尽快投入应用。
本次研究报告的作者、世卫组织助理总干事玛丽－波勒·基尼说，尽管这项成果来得有点晚，许多人已经在西非埃博拉疫情中失去生命，但这至少能保证下一次埃博拉疫情来袭时，人们不会束手无策。埃博拉
防范措施
控制传播
控制“埃博拉”的扩散，首先要密切注意世界埃博拉病毒疫情动态，加强国境检疫，暂停进口侯子主要限制来自疫区的侯子，到目前为止还没发现除灵长类动物以外的其他动物是埃博拉病毒的宿主。对有出血症状的可疑病人，应隔离观察。一旦确诊应及时报告卫生部门，对病人进行zui严格的隔离，即使用带有空气滤过装置的隔离设备。医护人员、实验人员穿好隔离服，可能时需穿太空服进行检验操作，以防意外。对与病人密切接触者，也应进行密切观察。
辅助性治疗
治疗首先是辅助性的，包括使病毒入侵zui小化，平衡电解质，修复损失的血小板以便防止出血，保持血液中氧元素含量，以及对并发症的治疗。排除个别病例，埃博拉康复者的血清在治疗疾病中并没有什么作用。干扰素对埃博拉也是无效的。在侯子试验中，凝固干扰素似乎能起一些作用，使原本*必死的感染猴中存活下33%。USAMRIID的科学家宣称，4只感染埃博拉病毒的猕猴中有3只康复。对埃博拉病毒病尚无*治疗方法，一些抗病埃博拉如干扰素和利巴韦林无效，主要是支持和对症治疗，包括注意水、电解质平衡，控制出血；肾衰竭时进行透析治疗等。

美国NovaBios埃博拉病毒试纸条

我司还提供其它进口或国产试剂盒：登革热、疟疾、乙脑、寨卡、黄热病、基孔肯雅热、克锥虫病、违禁品滥用、肺炎球菌、军团菌等试剂盒以及日本生研细菌分型诊断血清、德国SiFin诊断血清、丹麦SSI诊断血清等产品。

想了解更多的NovaBios产品及服务请扫描下方二维码：

【公司名称】 广州健仑生物科技有限公司
【市场部】    杨永汉

【】 
【腾讯  】 2042552662
【公司地址】 广州清华科技园创新基地番禺石楼镇创启路63号二期2幢101-103室

After confirming the validity of the above test results, the researchers extended the vaccination to children over 6 years of age, and 1677 were vaccinated immediay, including 194 children. The results show that they have also been effectively protected against Ebola haemorrhagic fever.
Approximay half of the 5837 people who had been vaccinated had mild adverse reactions such as headache, fatigue and muscle soreness. Individuals were more adversely affected, but their bodies recovered within days and did not produce long-term effects. In the case of people who have not been vaccinated, a total of seven people suffering from Ebola haemorrhagic fever.
US Merck has produced a number of US and EU certification, which is conducive to the relevant regulatory agencies to speed up the review of this new vaccine, so that it is put into use as soon as possible.
"Although the results have come a bit late, many people have lost their lives in the Ebola epidemic in West Africa, but at least it will guarantee the next time," said Mary Paul Polly Gini, the assistant director of the study and the WHO Assistant Director-General. When the Bora epidemic struck, people would not be helpless. Ebola
Precautions
Control propagation
Control the spread of "Ebola", we must first pay close attention to the world Ebola virus epidemic dynamics, strengthen the border quarantine, suspended imports of the main son of the transfer from the epidemic Hou son, so far not found in addition to primates The other animals are the hosts of the Ebola virus. Suspected patients with bleeding symptoms should be isolated and observed. Once the diagnosis should be promptly reported to the health sector, the patient's most stringent isolation, that is, with the use of air filtration device isolation equipment. Health care workers, experimental staff wear comfortable clothing, may need to wear a space suit for inspection operations, to prevent accidents. Close contact with patients should also be closely observed.
Adjuvant therapy
Treatment is first auxiliary, including minimizing virus invasion, balancing the electrolyte, repairing the lost plaets in order to prevent bleeding, maintain oxygen levels in the blood, and treat the complications. Elimination of individual cases, Ebola rehabilitation of the serum in the treatment of disease and no effect. Interferon is also ineffective for Ebola. In the Houzi test, coagulation interferon seems to play some role, so that the original * of the infected monkeys survived 33%. USAMRIID scientists claimed that four infected Ebola virus monkeys in the three rehabilitation. There is no specific treatment for Ebola virus disease, some resistance to Ebola such as interferon and ribavirin ineffective, mainly support and symptomatic treatment, including attention to water, electrolyte balance, control bleeding; renal failure when dialysis Treatment and so on.